Related Experiment Video
Updated: Jun 26, 2026

Echocardiographic Evaluation of Atrial Communications before Transcatheter Closure
Published on: February 8, 2022
Long-Term Outcomes Following Transcatheter Closure of Small Perimembranous Ventricular Septal Defects
Worakan Promphan1,2, Kanjarut Wongwaitaweewong3, Aishath Eleena1,2
1Department of Medical Services, Pediatric Heart Center, Queen Sirikit National Institute of Child Health, Ministry of Public Health, Mueang Nonthaburi, Thailand.
Abstract:
Transcatheter device closure is an off-label alternative therapy for perimembranous ventricular septal defect (PMVSD); we evaluated its long-term outcomes. Patients with PMVSDs who underwent transcatheter closure at our institutions between 2009 and 2016 were retrospectively reviewed. Patient demographics, procedural details, and follow-up outcomes were analysed. We identified 157 patients (51.6% male) with a median age of 7.4 years [interquartile range (IQR) 4-12] and median body weight of 23 kg (IQR 15-42.4) at procedure. Median defect diameter was 6 mm (IQR 5.0-8.0) and 4.0 mm (IQR 3.0-5.0) at the left and right ventricular side, respectively (mean Qp/Qs 1.5 ± 0.6). Procedure success rate was 96.8%. Of five unsuccessful cases, two required surgery-one for gross haematuria and one for heart block-while three failed due to anatomical constraints. Median follow-up was 5 years (IQR 4.0-6.0). Post-closure, 53 patients (33.7%) had residual shunts (90.6% trivial-to-small and 9.4% moderate shunts, regressing to small by the 3 year follow-up). Residual shunts were significantly more frequent with Nit-Occlud® Lê VSD coil (P < 0.05). New-onset tricuspid regurgitation (NTR) and aortic regurgitation (NAR) were observed in 33 (22%) and 15 (10.9%) patients, respectively. Severe NTR persisted in three patients (2.7%), while NAR was mostly trivial-to-mild, except in one case, requiring surgical correction 1 year post-procedure. Transcatheter closure of small PMVSDs is a valuable option for select patients using various devices. Nit-Occlud® Lê VSD coil showed higher residual shunt rates. NAR and NTR are rare but require close monitoring, as improvement is expected over time.

